Advertisement
Advertisement
ALNY
Alnylam Pharmaceuticals, Inc.
320.47
USDSponsored
-6.83
-2.09%
Mar 05, 16:00 UTC -5
Closed
After-Market
318.63
-1.83
-0.57%
ALNY Earnings Reports
Positive Surprise Ratio
ALNY beat 21 of 40 last estimates.
53%
Next Report
Date of Next Report
Apr 29, 2026
Estimate for Q1 26 (Revenue/ EPS)
$1.14B
/$1.03
Implied change from Q4 25 (Revenue/ EPS)
+4.24%
/+25.61%
Implied change from Q1 25 (Revenue/ EPS)
+92.46%
/-334.09%
Alnylam Pharmaceuticals, Inc. earnings per share and revenue
On Feb 12, 2026, ALNY reported earnings of 0.82 USD per share (EPS) for Q4 25, missing the estimate of 1.14 USD, resulting in a -28.48% surprise. Revenue reached 1.10 billion, compared to an expected 1.20 billion, with a -8.29% difference. The market reacted with a -4.28% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 16 analysts forecast an EPS of 1.03 USD, with revenue projected to reach 1.14 billion USD, implying an increase of 25.61% EPS, and increase of 4.24% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Liquidia Corporation Common Stock
Report Date
Mar 05, 2026 For Q4 25
Estimate
$0.18
Actual
$0.15
Surprise
-18.48%
Kura Oncology, Inc.
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.62
Actual
-$0.92
Surprise
-47.84%
CorMedix Inc.
Report Date
Mar 05, 2026 For Q4 25
Estimate
$0.83
Actual
$0.61
Surprise
-26.73%
REGENXBIO Inc.
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.97
Actual
-$1.30
Surprise
-33.31%
Lexicon Pharmaceuticals, Inc.
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.07
Actual
-$0.04
Surprise
+43.18%
Contineum Therapeutics, Inc. Class A Common Stock
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.41
Actual
-$0.49
Surprise
-18.41%
Verastem, Inc.
Report Date
Mar 04, 2026 For Q4 25
Estimate
-$0.53
Actual
-$0.50
Surprise
+7.32%
Lineage Cell Therapeutics, Inc.
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.05
Actual
$0.00
Surprise
+100.00%
Atea Pharmaceuticals, Inc. Common Stock
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.54
Actual
-$0.56
Surprise
-5.44%
Aligos Therapeutics, Inc. Common Stock
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$1.88
Actual
-$1.91
Surprise
-1.11%
FAQ
What were Alnylam Pharmaceuticals, Inc.'s earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Alnylam Pharmaceuticals, Inc. reported EPS of $0.82, missing estimates by -28.48%, and revenue of $1.10B, -8.29% below expectations.
How did the market react to Alnylam Pharmaceuticals, Inc.'s Q4 2025 earnings?
The stock price moved down -4.28%, changed from $322.28 before the earnings release to $308.48 the day after.
When is Alnylam Pharmaceuticals, Inc. expected to report next?
The next earning report is scheduled for Apr 29, 2026.
What are the forecasts for Alnylam Pharmaceuticals, Inc.'s next earnings report?
Based on 16
analysts, Alnylam Pharmaceuticals, Inc. is expected to report EPS of $1.03 and revenue of $1.14B for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement